Romiplostim as a treatment for immune thrombocytopenia: a review
Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune thrombocytopenia” (ITP) is an au...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-01-01
|
| Series: | Journal of Blood Medicine |
| Online Access: | http://www.dovepress.com/romiplostim-as-a-treatment-for-immune-thrombocytopenia-a-review-peer-reviewed-article-JBM |
| _version_ | 1811250461453320192 |
|---|---|
| author | Chalmers S Tarantino MD |
| author_facet | Chalmers S Tarantino MD |
| author_sort | Chalmers S |
| collection | DOAJ |
| description | Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune thrombocytopenia” (ITP) is an autoimmune disorder that leads to peripheral destruction, as well as a decreased production of platelets. ITP most commonly presents as mild mucocutaneous bleeding. Though it is rare, the leading cause of mortality in persons with ITP is intracranial hemorrhage and those that do not respond to therapy are at increased risk. Our understanding of the pathophysiology of ITP has evolved immensely, especially over the last 60 years. The discovery of the platelet-production stimulator, thrombopoietin (TPO), lent clarity to an earlier hypothesis that inhibition of platelet production at the level of the megakaryocyte, at least in part, accounts for thrombocytopenia in adults with ITP. This facilitated the development of TPO-based therapies to treat ITP. Thrombopoietin receptor agonists are one of the most recent treatments to enter the landscape. Original production of a recombinant human TPO was halted after clinical trials revealed the untoward effect of autoantibodies to the recombinant human TPO with cross-reactivity to endogenous TPO. Next-step development focused on stimulation of the TPO receptor with fewer immunogenic agents. Currently, two such thrombopoietin receptor agonists, romiplostim and eltrombopag, are licensed in the USA to treat thrombocytopenia in adults with persistent or chronic ITP. Ongoing research will assess their efficacy in other immune-mediated and nonimmune-mediated primary and secondary thrombocytopenias.Keywords: thrombopoietin, thrombopoietin receptor agonist, megakaryocyte, peptibody |
| first_indexed | 2024-04-12T16:05:02Z |
| format | Article |
| id | doaj.art-1e56c9e3956b47448193529ebe0f1415 |
| institution | Directory Open Access Journal |
| issn | 1179-2736 |
| language | English |
| last_indexed | 2024-04-12T16:05:02Z |
| publishDate | 2015-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Blood Medicine |
| spelling | doaj.art-1e56c9e3956b47448193529ebe0f14152022-12-22T03:26:05ZengDove Medical PressJournal of Blood Medicine1179-27362015-01-012015default374420040Romiplostim as a treatment for immune thrombocytopenia: a reviewChalmers STarantino MDSarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune thrombocytopenia” (ITP) is an autoimmune disorder that leads to peripheral destruction, as well as a decreased production of platelets. ITP most commonly presents as mild mucocutaneous bleeding. Though it is rare, the leading cause of mortality in persons with ITP is intracranial hemorrhage and those that do not respond to therapy are at increased risk. Our understanding of the pathophysiology of ITP has evolved immensely, especially over the last 60 years. The discovery of the platelet-production stimulator, thrombopoietin (TPO), lent clarity to an earlier hypothesis that inhibition of platelet production at the level of the megakaryocyte, at least in part, accounts for thrombocytopenia in adults with ITP. This facilitated the development of TPO-based therapies to treat ITP. Thrombopoietin receptor agonists are one of the most recent treatments to enter the landscape. Original production of a recombinant human TPO was halted after clinical trials revealed the untoward effect of autoantibodies to the recombinant human TPO with cross-reactivity to endogenous TPO. Next-step development focused on stimulation of the TPO receptor with fewer immunogenic agents. Currently, two such thrombopoietin receptor agonists, romiplostim and eltrombopag, are licensed in the USA to treat thrombocytopenia in adults with persistent or chronic ITP. Ongoing research will assess their efficacy in other immune-mediated and nonimmune-mediated primary and secondary thrombocytopenias.Keywords: thrombopoietin, thrombopoietin receptor agonist, megakaryocyte, peptibodyhttp://www.dovepress.com/romiplostim-as-a-treatment-for-immune-thrombocytopenia-a-review-peer-reviewed-article-JBM |
| spellingShingle | Chalmers S Tarantino MD Romiplostim as a treatment for immune thrombocytopenia: a review Journal of Blood Medicine |
| title | Romiplostim as a treatment for immune thrombocytopenia: a review |
| title_full | Romiplostim as a treatment for immune thrombocytopenia: a review |
| title_fullStr | Romiplostim as a treatment for immune thrombocytopenia: a review |
| title_full_unstemmed | Romiplostim as a treatment for immune thrombocytopenia: a review |
| title_short | Romiplostim as a treatment for immune thrombocytopenia: a review |
| title_sort | romiplostim as a treatment for immune thrombocytopenia a review |
| url | http://www.dovepress.com/romiplostim-as-a-treatment-for-immune-thrombocytopenia-a-review-peer-reviewed-article-JBM |
| work_keys_str_mv | AT chalmerss romiplostimasatreatmentforimmunethrombocytopeniaareview AT tarantinomd romiplostimasatreatmentforimmunethrombocytopeniaareview |